At the news
? BEARISHIMPACT 8/10 8-K filed Apr 3, 2026 at 16:02 ET
Phreesia reported Q4 revenue of $127.1M (16% YoY growth) but missed EPS estimates with $0.02 vs $0.31 expected, driven by higher costs. The company lowered its FY2027 revenue guidance to $510-520M (from $545-559M) due to reduced pharma marketing spend, particularly in vaccines and GLP-1 drugs, but maintained its Adjusted EBITDA guidance of $125-135M through cost efficiencies from AI-driven automation.
- Q4 revenue: $127.1M (+16% YoY), but EPS of $0.02 missed consensus of $0.31 by 93.5%
- Lowered FY2027 revenue guidance to $510-520M (down $35-49M) due to reduced pharma client spending commitments
- Maintained Adjusted EBITDA guidance of $125-135M despite revenue cut, citing AI-driven efficiency gains
- Network solutions revenue under pressure from vaccine and GLP-1 drug marketing pullbacks
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access